Clinical trial NCT03856229: Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS
Official title: Shortened Steroid Therapy in Patients With Moderate and Severe Pneumonia Due to P. Jirovecii Associated With HIV / AIDS
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Pneumocystis
HIV/AIDS
Steroid
Keywords: HIV/AIDS
PCP treatment
Steroids for PCP
Lead sponsor: Centro de Investigación en. Enfermedades Infecciosas, Mexico
Sponsor class: OTHER_GOV
First posted: 2019-02-27
Enrollment: 196
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: After obtaining the informed consent. The subjects will be randomized 6 days after starting treatment for PCP with trimethoprim/ sulfamethoxazole plus prednisone or methylprednisolone. Stratified randomization will be generated by an electronic system, in blocks of 6 and 8, and a 1:1 ratio, according to the CD4+ T cell count (less or more than 50 cells/mm3 and assigned to each group:

* Group A or Conventional Steroids use (CoSt). Patients will receive 21 days of steroid treatment.
* Group B or Shortened Steroids use (SSt). Subjects with moderate PCP will receive 8 days of steroids and subjects with severe PCP 14 days of steroids.
Primary purpose: TREATMENT

Brief summary: The treatment guidelines for Pneumocystis pneumonia (PCP) suggest adding 40mg of prednisone (or its equivalent in methylprednisolone) twice per day on days 1 through 5, 40 mg days 6 through 10, and 20 mg daily on days 11 through 21 in subjects with moderate and serious PCP. Steroids have shown to improve clinical outcome and reduction in mortality in HIV-infected patients the effectiveness of adjuvant steroid treatment for PCP has been observed if it starts within the first 24 to 48 hours. Possibly, there is a long-term benefit with their use in the recovery of function and limitation of chronic pulmonary complications; recently, benefits have been observed in decreasing the incidence of Inflammatory Immune Reconstitution Syndrome (IRIS) due to Mycobacterium tuberculosis. On the other hand, steroids could increase the morbidity related to adverse reactions as well as paradoxical worsening of associated herpes virus infection, which are attributed to IRIS or as a result of immunosuppression generated by their use. Recently, it has been shown that gradually steroids withdrawal is not necessary in patients who have received less than 21 days of treatment.

This non-inferiority work aims to confirm the null hypothesis that a reduced steroid scheme in patients with moderate PCP (8 days) and severe pneumonia (14 days) is sufficient to limit long-term ventilatory complications and acute postinflammatory syndrome, compared to the conventional 21-day scheme. It also has been hypothesized that it could be associated with fewer cases of IRIS due to herpes virus type 1,2,3 and 8.

Detailed description: The investigators selected hospitalized subjects with confirmed or suspected moderate or severe PCP: the diagnostic certainty will be based on the following criteria:

Proved PCP. Defined as cases with presence of P. jirovecii cysts in bronchial alveolar lavage (BAL) exams or lung biopsy.

Possible PCP. Defined by the following two criteria: 1) the presence of three of four items: cough, fever, dyspnea and compatible radiological or tomographic findings 2) associated clinical improvement after the onset of trimethoprim/sulfamethoxazole (TMP / SMX).

Probable PCP. Defined as the presence of one of the two previous criteria, without other identified microorganisms.

The radiological or tomographic findings compatible with PCP are: presence of bilateral reticular infiltrate, ground glass, crazy paving pattern and presence of bullae, cysts or spontaneous pneumothorax.

The microbiological findings will be the identification of cysts in the Grocott stain or a positive immunofluorescence test (IFA).

Patients will be classified as moderate PCP when the partial pressure of oxygen (PaO2) is less than 70 mmHg and the alveolar arterial difference (Da-a) is greater than 35 mmHg and severe PCP when it is greater than 45 mmHg.

The sample size was calculated for non-inferiority tests to a tail with an estimated mortality of 16% for both groups; using a Z alpha in 1.65 and Z beta in 1.645, with a non-inferiority margin of 0.6; resulting in 98 subjects per group.

After obtaining the informed consent, patients will be randomized accordingly to their CD4+ T cell count (less or more than 50 cells/mm3 and assigned to each group:

* Group A or Conventional Steroids use (CoSt).patients will receive 21 days of steroid treatment.
* Group B or Shortened Steroids use (SSt). Subjects with moderate PCP will receive 8 days of steroids and subjects with severe PCP 14 days of steroids.

The equivalent prednisone doses of systemic steroids will be recorded, as well as the duration of their administration since it could be modified according to the criteria of the treating physicians; demographic data, the start date of ART (Antiretroviral Therapy), and the presence of other opportunistic, nosocomial and co-infections will also be recorded.

The laboratory data that will be recorded at the time of diagnostic suspicion of PCP will be: CD4+ T cell count, HIV viral load, lactate dehydrogenase (LDH), C-reactive protein (PCRe), pAO2, Da-aO2.

Once the patient has been discharged, the patient will be scheduled to continue ambulatory, conventional follow-up at 90, 180 and 360 days after starting the ART and to evaluate secondary outcomes.

Once 50% of the sample size has completed 30 days of follow-up, a preliminary analysis will be conducted to assess safety and efficacy; if differences in the mortality are observed, the study will be terminated.

Eligibility criteria: Inclusion Criteria:

* Older than 18 years
* To have a gasometry at the admission that confirms moderate or severe PCP.
* Patients receiving trimethoprim / sulfamethoxazole in doses of 15 to 20 mg / kg per day from the first 24 hours after admission.
* Patients who have begun adjuvant treatment with steroids in the first 48 hours after admission.
* No history of chronic pulmonary disease.
* APACHE at hospitalization less than 20 points.

Exclusion Criteria:

* Allergic to TMP/SMX, who have not tolerated desensitization.
* History of inflammatory, infectious, autoimmune or neoplastic diseases except Kaposi's sarcoma, which merit the chronic use of steroids.
* Pleural or pericardial effusion and meningitis from any cause.
* Septic shock not related to PCP.
* Subjects who during the hospitalization have been diagnosed with any neoplasia (except Kaposi´s sarcoma)

Primary outcomes:
measure: Cumulative incidence of Mortality at 30 days
timeFrame: 30 days
Secondary outcomes:
measure: Cumulative incidence of Mortality at 90 days
timeFrame: 90 days
measure: Cumulative incidence of mortality at 360 days
timeFrame: 360 days
measure: Cumulative incidence of mortality by CMV pneumonitis
timeFrame: 360 days
measure: Cumulative incidence of mortality by CD4+T cell count
timeFrame: 360 days
measure: Cumulative incidence of mortality by PCP severity
timeFrame: 360 days
measure: Time of intubation
timeFrame: 90 days
measure: Time of intubation stratified by PCP severity
timeFrame: 90 days
measure: Number of participants with ventilatory requirements, stratified by the CD4+ T cell count
timeFrame: 90 days
measure: Number of participants with ventilatory requirements stratified by the CMV coinfection
timeFrame: 90 days
measure: Media of arterial oxygenation
timeFrame: 90 days
measure: Media of arterial oxygenation, stratified by PCP severity
timeFrame: 90 days
measure: Media of arterial oxygenation, stratified by CD4+ T cell Count
timeFrame: 90 days
measure: Media of arterial oxygenation, stratified by the CMV pneumonitis
timeFrame: 90 days
measure: Pulmonary function
timeFrame: 360 days
measure: Pulmonary function changes
timeFrame: 360 days
measure: Pulmonary function by spirometry, stratified by CD4+ T cell count
timeFrame: 360 days
measure: Pulmonary function by spirometry, stratified by PCP severity
timeFrame: 360 days
measure: Pulmonary function by spirometry, stratified by CMV pneumonitis
timeFrame: 360 days
measure: Changes in diffusing lung capacity of carbon monoxide
timeFrame: 360 days
measure: Changes in diffusing lung capacity of carbon monoxide by CMV coinfection
timeFrame: 360 days
measure: Changes in diffusing lung capacity of carbon monoxide by the PCP severity
timeFrame: 360 days
measure: Changes in diffusing lung capacity of carbon monoxide by CD4+ cell count
timeFrame: 360 days
measure: IRIS
timeFrame: 360 days
measure: Herpes virus dynamic
timeFrame: 90 days
Other outcomes:
Locations:
city: Mexico
country: Mexico
facility: Centro de Investigacion en Enfermedades Infecciosas
Study officials:
affiliation: Instituto Nacional de Enfermedades Respiratorias
name: Gustavo Reyes-Teran, M.D.
role: PRINCIPAL_INVESTIGATOR
References: